Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
US Department of Justice
Chinese Patent Office
McKinsey
Merck
Express Scripts
Fish and Richardson
Moodys
McKesson

Generated: August 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Esmolol formulation
Abstract:An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.
Inventor(s): Liu; Jie (Scotch Plains, NJ), Pejaver; Satish K. (Bridgewater, NJ), Owoo; George (North Plainfield, NJ)
Assignee: Baxter International Inc. (Deerfield, IL)
Application Number:10/016,260
Patent Claims: 1. An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, having a pH between 3.5 and 6.5 comprising: a. 0.1-500 mg/ml methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy]phenylpropionate hydrochloride (esmolol hydrochloride); b. 0.01-2 M buffering agent; and c. 1-500 mg/ml osmotic-adjusting agent.

2. The pharmaceutical composition of claim 1, wherein the pH is between 4.5 and 5.5.

3. The pharmaceutical composition of claim 1, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine.

4. The pharmaceutical composition of claim 1, wherein the osmotic-adjusting agent comprises at least one of sodium chloride, dextrose, sodium bicarbonate, calcium chloride, potassium chloride, sodium lactate, Ringer's solution and lactated Ringer's solution.

5. The pharmaceutical composition of claim 3, wherein the osmotic-adjusting agent comprises at least one of sodium chloride, dextrose, sodium bicarbonate, calcium chloride, potassium chloride, sodium lactate, Ringer's solution and lactated Ringer's solution.

6. The pharmaceutical composition of claim 1 comprising: a. 0.1-100 mg/ml esmolol hydrochloride; b. 0.01-0.5 M buffering agent; and c. 1-100 mg/ml osmotic-adjusting agent.

7. The pharmaceutical product of claim 1 comprising: a. 100-500 mg/ml esmolol hydrochloride; b. 0.5-2 M buffering agent; and c. 50-500 mg/ml osmotic-adjusting agent.

8. The pharmaceutical composition of claim 1, wherein the composition is provided in a heat sterilized container.

9. The pharmaceutical composition of claim 8, wherein the container is a vial, ampul, bag, bottle or syringe.

10. The pharmaceutical composition of claim 9, wherein the container is from 1-500 ml in volume.

11. The pharmaceutical composition of claim 4, having a pH of about 5 and comprising about 100-250 mg/ml of esmolol hydrochloride and 0.5-2 M buffering agent and 50-500 mg/ml osmotic-adjusting agent.

12. An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, having a pH of about 5.0 and comprising about 1-20 mg/ml esmolol hydrochloride, 0.02-0.1 M buffering agent and 1-100 mg/ml osmotic-adjusting agent, wherein the osmotic-adjusting agent comprises at least one of sodium chloride, dextrose, sodium bicarbonate, calcium chloride, potassium chloride, sodium lactate, Ringer's solution and lactated Ringer's solution.

13. A method for preparing an aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising forming an aqueous composition having a pH between 3.5 and 6.5 comprising 0.1-500 mg/ml methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), 0.01-2 M buffering agent, and 1-500 mg/ml osmotic-adjusting agent in a sealed container and autoclaving for a period of time sufficient to render the composition sterile.

14. The method of claim 13, wherein the composition has a pH between 4.5 and 5.5.

15. The method of claim 13, wherein autoclaving is carried out a temperature ranging from 115.degree. C. to 130.degree. C. for a period of time ranging from 5 to 40 minutes.

16. The method of claim 14, wherein autoclaving is carried out a temperature ranging from 115.degree. C. to 130.degree. C. for a period of time ranging from 5 to 40 minutes.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Chubb
UBS
Queensland Health
Mallinckrodt
Dow
Farmers Insurance
Novartis
Julphar
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot